A prospective, randomized controlled, multicenter study comparing the efficacy of two radiotherapy dose regimens for bone metastases of liver cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109100

Enrollment

Unknown

Registered

2025-09-11

Start date

2025-09-15

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastasis, Liver cancer

Interventions

Group 1:SBRT with a dose of 40Gy administered in 5 fractions

Group 2:SBRT with a dose of 34Gy administered in 3 fractions

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with liver cancer who have bone metastasis confirmed by two imaging examinations; 2. Age>=18 years old; 3.KPS>=60; 4. Expected survival > 3 months; 5. No surgical treatment; 6. No radiotherapy; 7. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who have participated in other clinical trials in the past and have not terminated the trial; 2. Patients with systemic or visceral metastasis or uncontrolled primary tumor; 3. Uncontrolled complications of liver cancer, such as: severe ascites, portal hypertension, hepatic encephalopathy, coagulation disorders with tendency, upper gastrointestinal bleeding and secondary infection, etc.; 4. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Easement of pain;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactPeng Zhenwei

The First Affiliated Hospital of Sun Yat-sen University

pzhenw@mail.sysu.edu.cn+86 20 8775 5766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026